VANCOUVER, June 11 /CNW/ - Biotech Holdings (the "Company", TSXV: BIO;
OTC BB: BIOHF) reports that it has launched a website, www.sucanonhealth.com,
for internet sales of Sucanon, a Type II diabetes drug.
Sucanon, which is broadly classed as an insulin-sensitizing drug, has
been shown to be an effective and very safe treatment for Type II Diabetes,
without the side-effects that are associated with several competing Type II
Diabetes medications including the glitazone medications which are now the
subject of a "black box" warning by the U.S. FDA. (see New York Times, June 7,
2007, page 1 and http://www.msnbc.msn.com/id/19090626/).
Sucanon has received regulatory approval in Mexico, is widely sold there
and has received the support of the Mexican Diabetes Federation. In addition,
an agreement has recently been signed for expansion of retail distribution to
four other Latin American markets as outlined in a news release of May 30,
2007 on yahoo http://biz.yahoo.com/prnews/070530/to380.html?.v=20, and on
Biotech Holdings' website, www.biotechltd.com.
The website www.sucanonhealth.com makes Sucanon available to Type II
diabetics, without prescription, in countries worldwide including the United
States and Canada which do not require regulatory approval for drugs that are
imported only for personal use and are not re-sold.
To learn more about or order Sucanon, see www.sucanonhealth.com.
This release has been approved by the Board of Directors of Biotech
The TSX Venture Exchange does not accept responsibility for the adequacy
or accuracy of this release.
Robert B. Rieveley, Pres.
On behalf of the Board of Directors
Any statements made in this release that are not based on historical fact
are forward-looking statements. Any forward-looking statements made in this
release represent management's best judgement as to what may occur in the
future. However, actual outcome and results are not guaranteed and are subject
to certain risks, uncertainties and assumptions and may differ materially from
what is expressed. There is no assurance that internet sales of Sucanon will
If you wish to be removed from Biotech Holdings' email news distribution
list, please reply by email, putting "remove" in the subject line.
For further information:
For further information: contact Austin Rand at Biotech Holdings,
1-888-216-1111 (toll-free) 8 a.m. to 4 p.m. Pacific time; For background
information on Biotech Holdings, or to receive news updates, see
www.biotechltd.com; Directors of the company can be reached by calling (604)